bioMérieux S.A. (BIM.PA) • EURONEXT
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold BIM.PA in your mock portfolio yet.
With a PE ratio of 21.32 and EPS of 3.36, bioMérieux S.A. appears reasonably valued for a profitable, established diagnostics company, but not obviously cheap. The valuation suggests the market expects steady, not explosive, earnings growth. Without explicit recent revenue and margin data, the picture is one of solid but unspectacular financial strength.
Despite a 3.9% gain over the last month, the current price of €71.65 is well below the 200‑day moving average of €94.11, indicating a longer‑term downtrend. This gap points to persistent selling pressure or a significant de‑rating over recent months. Without evidence of a sustained reversal pattern or over‑sold technicals (e.g., RSI data), the technical setup remains cautious.
Alternative data for bioMérieux S.A. show encouraging operational and brand‑engagement signals. Job openings are up 10.3% month over month, suggesting expansion or investment in growth initiatives. Social media metrics are broadly stable to slightly positive, with modest follower growth on most platforms and a very large LinkedIn base that underscores strong professional and industry visibility.
Overall, the picture for bioMérieux S.A. is neutral: operational and alternative data indicators lean constructive, but the stock’s technical profile remains weak with the price far below its 200‑day moving average. The valuation and earnings profile suggest a solid, profitable company, yet the market is still discounting the shares relative to their recent historical trend.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started